Information for "Phase III research associated with adjuvant gemcitabine compared with adjuvant uraciltegafur in individuals with entirely resected pathological point IBIIIA nonsmall mobile carcinoma of the lung WJTOG0101"
From EECH Central
Basic information
Display title | Phase III research associated with adjuvant gemcitabine compared with adjuvant uraciltegafur in individuals with entirely resected pathological point IBIIIA nonsmall mobile carcinoma of the lung WJTOG0101 |
Default sort key | Phase III research associated with adjuvant gemcitabine compared with adjuvant uraciltegafur in individuals with entirely resected pathological point IBIIIA nonsmall mobile carcinoma of the lung WJTOG0101 |
Page length (in bytes) | 3,225 |
Page ID | 1377925 |
Page content language | English (en) |
Page content model | wikitext |
Indexing by robots | Allowed |
Number of redirects to this page | 0 |
Page protection
Edit | Allow all users (infinite) |
Move | Allow all users (infinite) |
Edit history
Page creator | Weightcloudy1 (Talk | contribs) |
Date of page creation | 14:11, 18 April 2024 |
Latest editor | Weightcloudy1 (Talk | contribs) |
Date of latest edit | 14:11, 18 April 2024 |
Total number of edits | 1 |
Total number of distinct authors | 1 |
Recent number of edits (within past 90 days) | 1 |
Recent number of distinct authors | 1 |